Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches
The company believes that the study findings support its patented DehydraTECH(TM) system as being the world’s fastest-acting nicotine through oral absorption and a safer nicotine alternative for the 1.1 billion smokers of the world Plans for a human trial are in the design process, and Lexaria intends to use existing capital to execute the study The global nicotine pouch market is expected to grow to a total revenue of $21.84 billion by the end of 2027, a CAGR growth of 30.7% over the forecast period A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) has announced the results…